Evidence map›Paper›PMID 29094315›Full record

Trial reportAdvances in therapy2017

Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.

Gregory J Feldman, Ana R Sousa, David A Lipson, Lee Tombs, Neil Barnes, John H Riley, Sadhana Patel, Ian Naya, Chris Compton, Bernardino Alcázar Navarrete

Registry-linked trialAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Advances in therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02799784 (A Randomized, Open-Label, 8-Week Cross-Over Study to Compare Umeclidinium/Vilanterol With Tiotropium/Olodaterol Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease), which is not on this map. Cited by 46 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02799784 phase4completednot on this map

A Randomized, Open-Label, 8-Week Cross-Over Study to Compare Umeclidinium/Vilanterol With Tiotropium/Olodaterol Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

TypeinterventionalSponsorGlaxoSmithKlineRan2016 to 2017Enrolled236ConditionsPulmonary Disease, Chronic ObstructiveArmsUMEC/VI, TIO/OLO, Albuterol/salbutamol
3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Joint longitudinal model-based meta-analysis of FEVJournal of pharmacokinetics and pharmacodynamics · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Early COPD diagnosis and treatment: A case report.Respiratory medicine case reports · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gregory J FeldmanS. Carolina Pharmaceutical Research, Spartanburg, SC, USA. gfeld3232@aol.com.
Ana R SousaRespiratory Research and Development, GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex, UK.
David A LipsonRespiratory Research and Development, GlaxoSmithKline, King of Prussia, PA, USA.
Lee TombsPrecise Approach Ltd, Birmingham, West Midlands, UK.
Neil BarnesGlobal Respiratory Franchise, GlaxoSmithKline, Brentford, Middlesex, UK.
John H RileyRespiratory Therapy Area Unit, GlaxoSmithKline Medicines Research Centre, GlaxoSmithKline, Stevenage, Hertfordshire, UK.
Sadhana PatelGlobal Respiratory Franchise, GlaxoSmithKline, Brentford, Middlesex, UK.
Ian NayaRespiratory Medicine, GlaxoSmithKline, Brentford, Middlesex, UK.
Chris ComptonGlobal Respiratory Franchise, GlaxoSmithKline, Brentford, Middlesex, UK.
Bernardino Alcázar NavarreteNeumología, Hospital de Alta Resolución de Loja, Granada, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe report the results of the first direct comparison of the once-daily fixed-dose long-acting muscarinic antagonist/long-acting β

methodsThis was a randomized, two-period crossover open-label study in symptomatic patients with COPD [age 40 years or older, postbronchodilator forced expiratory volume in 1 s (FEV

resultsIn total, 236 patients (mean age 64.4 years, 60% male) were included in the intent-to-treat population and 227 were included in the PP population. UMEC/VI treatment was noninferior in the PP population and superior in the intent-to-treat population to TIO/OLO treatment with regard to trough FEV

conclusionIn this first direct comparison of two once-daily fixed-dose LAMA/LABA combinations, superiority was observed for the primary end point of trough FEV

trial registrationClinicalTrials.gov identifier NCT02799784.

fundingGlaxoSmithKline.

Indexed as

Administration, InhalationAgedBenzoxazinesBenzyl AlcoholsBronchodilator AgentsChlorobenzenesCross-Over StudiesDouble-Blind MethodDrug CombinationsFemaleForced Expiratory VolumeHumansMaleMiddle AgedNebulizers and VaporizersPulmonary Disease, Chronic ObstructiveBenzoxazinesBenzyl AlcoholsBronchodilator AgentsChlorobenzenesDrug CombinationsGSK573719QuinuclidinesTiotropium Bromidetiotropium-olodaterolvilanterolBronchodilationCOPDLABALAMALong-acting muscarinic antagonistLong-acting β2-agonistOlodaterolTiotropiumUmeclidiniumVilanterol

Identifiers

PMID29094315
PMCPMC5702366

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.